Ipsen Doubles Down On FOP With Blueprint Pact
Deal could be worth up to $535m
With the addition of BLU-782 to its soon-to-be filed fibrodysplasia ossificans progressiva drug palovarotene, Ipsen hopes to expand treatment options for patients with the rare bone disease.
